6533b835fe1ef96bd129f39f

RESEARCH PRODUCT

Immunotherapy of Malignant Melanomas

K H Meyer Zum BüschenfeldeWolfgang Dippold

subject

Gangliosidebiologymedicine.drug_classbusiness.industryMelanomamedicine.medical_treatmentMelanoma antigenImmunotherapyMonoclonal antibodymedicine.diseaseAntigenmedicinebiology.proteinCancer researchHuman melanomaAntibodybusiness

description

A large number of antigens on human melanoma cells have been identified by means of monoclonal antibody technology [18, 21]. The availability of monoclonal antibodies has rapidly led to clinical investigations. Experience with monoclonal antibodies in the treatment of patients with melanoma is limited [4, 9, 10, 12, 13, 17, 19] because only small groups of patients have been treated so far. According to these studies, treatment with ganglioside antibodies appears most promising.

yearjournalcountryeditionlanguage
1989-01-01
https://doi.org/10.1007/978-3-642-73721-3_7